Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation zaps prostate cancer spots in men not helped enough by hormone drugs

NCT ID NCT07644754

Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving radiotherapy to the prostate and to cancer spots seen on PET scans can help men with metastatic prostate cancer whose PSA levels remain high after six months of hormone therapy. Participants continue their hormone treatment and receive three PSMA-PET scans along with targeted radiation. The main goal is to see if the cancer stops growing on imaging one year after radiotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy
What this could lead to
If successful, this approach could offer a way to better control metastatic prostate cancer by targeting both the primary tumor and remaining cancer spots with radiation.
What could go wrong
This is a small, early-phase study with only 27 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue or local irritation, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Feb 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prostate adenocarcinoma * de novo metastasized prostate cancer (at least 4 osseous metastases +/- lymphonodal metastases) * first-line combined antihormonal therapy (ADT + ARPI) for six months * PSA \> 0,2 ng/ml after six months of combined ADT/ARPI therapy * multimetastasized disease stage without visceral metastases on imaging at first diagnosis (PET, CT, or bone scan) * \<16 osseous/lymphnodal metastases on response assessment imaging (PSMA-PET/CT) after six months of combined antihormonal therapy Exclusion Criteria: * neuroendocrine histology * visceral metastases (M1c) * prior radiotherapy to the pelvis * PSA \< 0,2 ng/ml after 6 months of combined antihormonal therapy * prior prostatectomy * contraindication against PSMA-PET/CT and/or radiotherapy to the prostate/metastases * HIFU or TUR-P within 6 months of study treatment * other active malignancy two years prior to study inclusion (except skin cancer in remission) * relevant GU/GI condition (active fistula or other) * known tumor predisposition syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Prostate cancer metastatic disease Prostate cancer metastatic to bone

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.